Mirum Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023

Rhea-AI Summary

Mirum Pharmaceuticals (Nasdaq: MIRM) announced its participation at the J.P. Morgan Healthcare Conference, scheduled for January 9-12, 2023, in San Francisco, CA. Mirum will present on January 10 from 1:30-2:10 p.m. PT.

Mirum focuses on developing therapies for rare liver diseases, with its approved treatment LIVMARLI® for cholestatic pruritus due to Alagille syndrome. The company has a pipeline of investigational treatments for liver diseases in children and adults.

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will present at the annual J.P. Morgan Healthcare Conference taking place January 9-12, 2023.

Presentation and Q&A Session

• Location: San Francisco, CA
• Date: Tuesday, January 10, 2023
• Time: 1:30-2:10 p.m. Pacific Time / 4:30-5:10 p.m. Eastern Time

Visit the Investors and Media section of Mirum’s corporate website for webcast links and additional information.

About Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare liver diseases. Mirum’s approved medication is LIVMARLI® (maralixibat) oral solution (LIVMARLI) which is approved in the United States for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) one year of age and older. The European Medicines Agency has also granted marketing authorization to Mirum for LIVMARLI for the treatment of cholestatic pruritus in patients with ALGS two months of age and older.

Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases affecting children and adults. LIVMARLI, an oral ileal bile acid transporter (IBAT) inhibitor, is currently being evaluated in clinical trials for pediatric liver diseases and includes the EMBARK Phase 2b clinical trial for patients with biliary atresia. In addition, Mirum has an expanded access program open across multiple countries for eligible patients with ALGS and PFIC.

Mirum’s second investigational treatment, volixibat, an oral IBAT inhibitor, is being evaluated in two potentially registrational studies including the VISTAS Phase 2b clinical trial for adults with primary sclerosing cholangitis and the VANTAGE Phase 2b clinical trial for adults with primary biliary cholangitis.

Follow Mirum on Twitter, Facebook, LinkedIn and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230103005794/en/

Investor Contacts:

Ian Clements, Ph.D.

ir@mirumpharma.com

Sam Martin

Argot Partners

ir@mirumpharma.com

Media Contact:

Erin Murphy

media@mirumpharma.com

Source: Mirum Pharmaceuticals, Inc.

FAQ

When will Mirum Pharmaceuticals present at the J.P. Morgan Healthcare Conference?

Mirum Pharmaceuticals will present on January 10, 2023, from 1:30-2:10 p.m. Pacific Time.

What is the focus of Mirum Pharmaceuticals' work?

Mirum Pharmaceuticals focuses on developing novel therapies for rare liver diseases.

Where is the J.P. Morgan Healthcare Conference being held?

The conference is taking place in San Francisco, CA.

What is LIVMARLI® and its indication?

LIVMARLI® is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome.

What are the investigational treatments in Mirum's pipeline?

Mirum's pipeline includes LIVMARLI for pediatric liver diseases and volixibat for adults with primary biliary cholangitis.